Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
This randomized phase I/II trial studies the side effects and best dose of veliparib when
given together with or without cisplatin and etoposide and to see how well they work in
treating patients with extensive stage small cell lung cancer or large cell neuroendocrine
non-small cell lung cancer that has spread to other parts of the body. Drugs used in
chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of
tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them
from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving cisplatin and etoposide with or without veliparib may work
better in treating patients with extensive stage small cell lung cancer or metastatic large
cell neuroendocrine non-small cell lung cancer.